My ePortfolio Register   

Understanding drug resistance genes in ovarian and breast cancer cells

Researchers from the People's Friendship University of Russia (RUDN University) have studied the mechanism of drug resistance for ovarian and breast cancer cells.

They discovered that these cancer cells have redox-dependent mechanism which is tasked with sustaining their drug resistance.

The results have been published in two articles in the journal of Free Radical Biology and Medicine.

Researchers from the RUDN University have found out one of reasons why chemotherapy (in particular, cisplatin) gradually stops affecting the cells of ovarian and breast tumours.

The authors study the biochemical mechanisms which allow tumour cells to develop resistance to antitumour drugs.

During chemotherapy, when using certain drugs, the tumour cells are affected by toxic and oxidative stress, which stop their functioning.

Sometime later, however, the cells "get used" to the drug action, which necessitates using stronger doses of the drug, which, in turn, negatively affects the patient's organism due to its toxic effect.

To stop the development of drug resistance, researchers need to learn operating the expression (the process of transferring hereditary information from DNA) of genes that control the cell viability.

Many mechanisms allow it, including the redox processes which regulate, in particular, the cell antioxidant defense, which protects the cell against oxidative stress so that it could function properly.

Without those "defender genes", it would be far easier for drugs to kill cancer cells.

The researchers hope that the process could eventually be controlled.

Some of these genes' expression changes happen when human ovarian cancer (SKOV-3) cells and human breast cancer (MCF-7) cells develop resistance to an antitumour drug, cisplatin.

Antitumour action of cisplatin is achieved in no small part by its pro-oxidant effect, meaning that it uses oxidative stress to destroy cells.

"As a result of development of the drug resistance in cancer cells, it was observed an increase in the gene expression encoding isoforms of thioredoxin and peroxiredoxin, which play an important role in the antioxidant defense system and the redox-dependent signalling." says Elena Kalinina, one of the article's authors, D.Sc., professor of T.T. Berezov Department of Biochemistry (RUDN University Institute of Medicine). "Significant increase in expression of such genes substantially contributes to forming a high level of antioxidant defense under development of cancer cell resistance to pro-oxidant action of cisplatin. Thus, the growth of expression of the Prx6 gene was observed in the resistant cells."

"The data obtained also points to a significant role of Prx1, Prx2 and Prx3 isoforms in the redox-dependent mechanisms of the resistance development of the cell lines."

The increase in gene expression points to the fact that isoforms of thioredoxin and peroxiredoxin participate in the development of cancer cell drug resistance.

The researchers note that this effect can also be considered as a part of a redox-dependent adaptive antioxidant response to the oxidative stress caused by cisplatin's pro-oxidant action.

"The results obtained significantly expand our fundamental knowledge of the sum total of molecular events in the mechanisms of death and formation of drug resistance for cancer cells and of the role redox-dependent systems in these processes" Prof Kalinina concluded.

These results, obtained by the researchers, in the future will enable us to improve the drug treatment programs for oncology patients.

Source: RUDN University

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence